Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells.
Mueller J, Schimmer RR, Koch C, Schneiter F, Fullin J, Lysenko V, Pellegrino C, Klemm N, Russkamp N, Myburgh R, Volta L, Theocharides AP, Kurppa KJ, Ebert BL, Schroeder T, Manz MG, Boettcher S.
Mueller J, et al. Among authors: volta l.
EMBO Mol Med. 2024 Mar;16(3):445-474. doi: 10.1038/s44321-024-00024-2. Epub 2024 Feb 14.
EMBO Mol Med. 2024.
PMID: 38355749
Free PMC article.